RITUXAN—FDA-APPROVED ACROSS MULTIPLE INDICATIONS IN NHL BASED ON 9 PIVOTAL TRIALS 1

RITUXAN is not recommended for use in patients with severe, active infections.

NEXT: Previously Untreated Follicular Lymphoma >